Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00240721
Other study ID # CR002248
Secondary ID
Status Completed
Phase Phase 3
First received October 14, 2005
Last updated June 6, 2011
Start date October 2000
Est. completion date September 2002

Study information

Verified date November 2010
Source Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to evaluate the effectiveness and safety of topiramate compared with placebo in the treatment of acute manic or mixed episodes in patients with Bipolar I Disorder.


Description:

This is a randomized, double-blind, placebo-controlled study to evaluate the effectiveness of two dose levels of topiramate (400 and 600 milligrams/day) compared with placebo in the treatment of acute manic or mixed episodes in patients with Bipolar I Disorder. The trial consists of 3 phases: a screening period; double-blind treatment for 12 weeks; and an optional open-label period of at least 6 months. Assessment of effectiveness include change from baseline to Day 21 for the Young Mania Rating Scale (YMRS) total score. Also included during the 12 week study are the Global Assessment Scale (GAS), Montgomery-Åsberg Depression Rating Scale (MADRS), Brief Psychiatric Rating Scale (BPRS), Clinical Global Impressions (CGI), and health-related quality of life measures at specified time intervals. Safety assessments include evaluation of adverse events, rate of withdrawal from the study due to adverse events, and vital signs (blood pressure and pulse) throughout the study, as well as changes in clinical laboratory tests (hematology, biochemistry, urinalysis), electrocardiograms (ECGs), and physical examinations at specified times. The study hypothesis is that the change from baseline in Young Mania Rating Scale (YMSR) total score at Day 21 will be significantly better for the topiramate groups than for the placebo group. Topiramate tablets (50 or 100 milligrams) or placebo, beginning at 50mg daily and increasing over the first week to a maximum of 400mg/day or 600mg/day, depending on study group. Maximum dosage continues up to 12 weeks. Dosage can be decreased or increased at investigator's discretion.


Recruitment information / eligibility

Status Completed
Enrollment 363
Est. completion date September 2002
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 16 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of Bipolar I Disorder by criteria of Diagnostic and Statistical Manual of Mental Diseases, 4th edition (DSM-IV), and currently experiencing a manic or mixed episode by DSM-IV and Structured Clinical Interview criteria

- experienced at least one previous manic or mixed episode

- Young Mania Rating Scale (YMSR) score >=20

- physically healthy

- females must be postmenopausal, surgically sterile, or using adequate contraceptive measures, and have a negative pregnancy test.

Exclusion Criteria:

- Diagnosis of alcohol or substance dependence (with the exception of nicotine or caffeine dependence) by DSM-IV criteria

- DSM-IV Axis I diagnosis of schizoaffective disorder or impulse control disorder

- experienced a manic episode while taking an antidepressant or psychostimulant drug

- no significant and untreated or unstable medical illness of the liver, kidney, heart, lungs, or endocrine system

- no hypersensitivity to topiramate or have previously participated in a topiramate study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
topiramate


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline to Day 21 for the Young Mania Rating Scale (YMRS) total score.
Secondary Change from baseline to Day 21 for scores on MADRS, BPRS, CGI, and GAS; response to treatment, indicated by not any longer meeting DSM-IV criteria for manic/mixed episode.
See also
  Status Clinical Trial Phase
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Recruiting NCT05345392 - Brain, Emotions, and Mind-Wandering N/A
Completed NCT05078450 - Mood Lifters Online for Graduate Students and Young Professionals N/A
Not yet recruiting NCT04551027 - Assessing the Effect of Compensatory Cognitive Intervention Among People With Severe Mental Illness N/A
Recruiting NCT03088657 - Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
Active, not recruiting NCT02542475 - Low Field Magnetic Stimulation: Open Label Study. Phase 1/Phase 2
Completed NCT00916552 - Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolar Disorder Phase 2
Completed NCT00202514 - Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms Phase 2/Phase 3
Completed NCT00217932 - Effectiveness of Divalproex Sodium (Depakote) in Treating Children With Temper Outbursts and Severe Mood Swings Phase 2
Completed NCT00006517 - Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD) N/A
Terminated NCT03898843 - Assisted Animal Therapy: ReAnimal N/A
Active, not recruiting NCT04358900 - Unobtrusive Monitoring of Affective Symptoms and Cognition Using Keyboard Dynamics (UnMASCK)
Recruiting NCT06360562 - Reconnecting to Ourselves and Others in Virtual Meetings (ROOM) N/A
Completed NCT05745103 - Optimizing Behavioral Healthcare Delivery Through Technology N/A
Suspended NCT03715400 - Mobile Virtual Positive Experiences for Anhedonia N/A
Enrolling by invitation NCT03736538 - Nitrous Oxide- Suicidal Ideation Phase 1
Completed NCT04601545 - The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method N/A
Completed NCT02566980 - Biological Triggers of Depression in Pregnancy
Completed NCT03743844 - Psychosocial Intervention for Women With Mood Disorders Seeking Treatment for Obesity N/A
Completed NCT05211063 - Effects of CROCUVIS+® on Computer Vision Syndrome, Sleep and Mood Disorders N/A